T he RAS 1s the prototype of a classic systemic endocrine network whose actions m the kidney and adrenal glands regulate blood pressure, intravascular volume, and electrolyte balance In contrast, TGF-P 1s consldered to be a prototypical cytokme, a peptlde signaling molecule, whose multiple actions on cells are mediated m a local or paracnne manner TGF-P exists m mammals m three lsoforms, TGF-/31, $2 and 433, that have largely overlapping functions In this review, we will use the generic term TGF-/3 because even where there are hints of lsoform-spec& actions, we believe the results need confirmation Recently, an explosion of new mformatlon has dramatically expanded and altered our understanding of the RAS and TGF-/3
For example, while the RAS was long thought to be entirely systemic, new data mdlcate that there 1s an intact RAS m many tissues whose acnons are entirely paracnne ' 2 TGF-/3, long thought to have only paracnne and autocnne effects, has now been shown to have wide-ranging systenuc (endocrine) effects 3 Furthermore, there 1s a blologtally rich and complex interaction between the RAS and TGF-P m which both act at various points to regulate the actlons of the other This mteractlon has great importance for understanding the vital roles that the RAS and TGF-P play m normal organ development, physiology, and tissue repalr However, the interplay between the RAS and TGF-P also has a dark side Actlvatlon of the RAS and generation of Ang II have long been known to play a role m the pathogenesls of hypertension and renal and cardiac fibrosis '-' Recently, TGF-/3 has been shown to be a uniquely powerful fibrogenlc cytokme ' TGF-P acts to simultaneously stimulate the synthesis of extracellular matrix, to inhibit the actions of proteases that degrade matrix, and to increase the expression of cell surface mtegnns that interact with matrix components Through these three effects, TGF-/3 rapidly causes the deposition of an exuberant extracelMar matnx Recent studies from our laboratory have shown that Ang II mfuslon strongly stimulates the production and actlvatlon of TGF-P m the kidney a Ang II blockade reduces TGF-P overexpresslon In kidney and heart, and there 1s now a consensus that TGF-P mediates a good deal of renal and cardiac fibrosis associated with actlvatlon of the RAS 9
In this review, we will focus on new mformatlon about the interaction of the RAS and TGF-/3
We will provide an overview of how the RAS and TGF-/3 act m the blologcal emergency of tissue mjury as "911" molecules to maintam TGF-/3 and Angotensm II Selected Abbrewatmns and Acronyms
Ang II = angmtensm II ACE = anglotensln-converting enzyme AT, = angmtensm II type 1 ATS = am-thymocyte serum JGA = JUXtaglOmerUlat' apparatus PA1 = plasmmogen actwator mhlbltor KAS = rem-angmtensm system TGF-P = transformmg growth factor-p tissue homeostasls We will propose that when inJury 1s repeated or continual, this interplay between the RAS and TGF-P causes continued activation that may result m chronic hypertension and progressive tissue fiblosls leading to organ failure We will provide evidence that the current pharmacological approaches to block the RAS are suboptimal and that, m addmon to blood pressure, normahzatlon of TGF-P should be part of the therapeutic goal Current evidence suggests that a combmatlon of RAS blockade with a separate agent to suppress TGF-P may be superior to RAS blockade alone Such a combmatlon may be required if progressive fibrotic diseases, such as diabetic nephropathy, are to be truly prevented, instead ofjust delayed
Biological
"911" Molecules
Maintenance of physlologcal and blochemlcal homeostasls 1s a key priority of hvmg organisms 3 In this regard, the RAS and TGF-P can be viewed as powerful effector molecules that act to preserve systemic and tissue homeostasls When there 1s a threat to homeostasls, an emergency "911" signal 1s sent, and the RAS and TGF-P respond by becoming activated The concept that the RAS and TGF-P are members of a "911" response team 1s Important because it anticipates the lmportance of cross-talk between the RAS and TGF-/3 as they carry out then blologlcal functions A wound 1s a good example of a blologcal emergency m which the independent "911" actions of the RAS and TGF-P can be easily observed In a systemic response, the RAS rapidly generates Ang II that acts by vasoconstrlctlon to maintain blood pressure and then later stimulates the secretion of aldosterone, resulting m an increase m intravascular volume In the wound, TGF-P 1s rapidly released by degranulatmg platelets where it does the followmg (1) automduces the production of TGF-/3 by local cells to amplify the blologcal effects, (2) chemoattracts monocyte/macrophages that debnde and stenhze the wound and fibroblasts that begin matrix synthesis, (3) causes the deposltlon of new matnx by simultaneously stlmuiatmg the synthesis of new matnx, mhlbltmg the proteases that degrade matrix, and modulating the numbers of mtegnn receptors to facilitate cell adhesion to the newly assembled matnx, (4) suppresses the promflammatory effects of mterleukm-1 and tumor necrosis factor, (5) regulates the actions of platelet-denved growth factor and fibroblast growth factor so that cell prollferatlon and angogenesls are coordlnated with matnx deposltlon, and (6) terminates the process when repair 1s complete and the wound 1s closed "I What 1s not apparent m the emergency paradigm of a wound 1s the slgmficant mterconnectlons (cross-talk) and overlappmg properties between the RAS and TGF-/I These mterconnectlons have only been discovered recently and are apparent at both the systemic and molecular levels and are especially apparent m the kidney In a series of articles, we have shown that TGF-/3's actions m causing matrix deposltlon m a heahng wound are the same actions that make TGF-/3 a powerful fibrogemc cytokme ','I Indeed, it IS the failure to terminate the production of TGF-P that dlstmgulshes normal tissue repair from fibrotic disease Evidence now indicates that the RAS and TGF-/3 coregulate each other's expression Thus, this interaction m the kidney may keep both systems activated long after the "911" response should have been terminated This sustained activity would lead to progressive fibrosis Transgemc animals, where the TGF-/31 gene 1s linked to the albumin promoter, were produced as a model of liver fibrosis I2 However, these ammals were found to have high plasma levels of TGF-P and to die of renal fibrosis before they exhlblted significant liver fibrosis, mdlcatmg that the kidney 1s partlcularly susceptible to overexpresslon of TGF-P " The mterrelatlonshlps of the RAS and TGF-P, which are the subject of this review, may explam this unique susceptlblhty of the ludney to TGF-/3 overexpresslon and why pharmacologcal suppression of the RAS and mhlbltlon of TGF-j3 are both therapeutic m fibrotic diseases of the kidney ',I4
Interactions of the RAS and TGF-/3 in the Kidney Fig 1 depicts the complex interplay between the RAS and TGF-P m the kidney Fluid shear stress, due to Increased pressure or flow, has been shown to activate both the RAS and TGF-/3 m endothehal cells " In the glomerular endothehum, actlvatlon of the RAS and TGF-P has been shown to play a role m the pathogenesls of glomerulonephntls and hypertensive injury 6 I6 " Volume depletion and restnctlon of potassium are two classic maneuvers that stimulate remn production and hypertrophy m the JGA m the ludney It was a complete surpnse when it was discovered that these stimuli also strongly induce the productlon of TGF-P m the JGA '"I') Co-locahzatlon of remn and TGF-/3 m the hypertrophlc JGA has also been described m a hypertensive human "' Treatment of rats with enalapnl, an ACE mhlbltor, further mcreased the expression of renm and TGF-P m the JGA ") This result indicates that m the JGA, it 1s not Ang II that 1s mducmg TGF-/3, but suggests that the production of rerun and TGF-P are coregulated Indeed, TGF-P sumulates the release of remn frcm kidney cortical slices and cultured Juxtaglomerular cells " " In a recent study, proremn transgemc rat5 had elevated levels of prorenm, were not hypertensive, and developed renal fibrosis, raising the posslbihty that stlmulatlon of TGF-j3 was involved "
There are other fascinating mterconnectlons between the RAS and TGF-j3 Ang II strongly induces TGF-P production m cultured cells and m VIVO ' It 1s thus likely that the tibrogemc effects that have been attributed to Ang 11 are actually mediated by TGF-P, as will be descllbed m detail late] Like Ang II, TGF-P stimulates the LontraLtlon of vascular smooth muscle cells and glomerular mesanglal cells " This suggests thdt release of TGF-/3 from the JGA might modulate the glomerulal nucroclrculation Indeed, the mtravenous mJectlon of high doses of TGF-/3 mto rats that were volume depleted produced a dramatic reduction m glomerular filtration rate 24 The rat? also developed severe retropentoneal fibroslr Sulp~cmgly, inJection of TGF-/3 had no effects m euvolemlc ratr The reason that TGF-P had such an effect m the presence of volume depletion 1s unclear but could be due to a synergistic effect between TGF-/3 and an activated RAS Another mterplay between the RAS and TGF-P 1s at the level of aldosterone Ang II stnnulates the production and release of aldosterone from the adrenal gland In contrast, TGF-/3 suppresses aldosterone production and strongly blocks the ablhty of Ang II to stimulate aldosterone by reducmg the number of Ang II receptors expressed m the adrenal gland " *' Furthermore, TGF-/3 acts to block the effects of aldosterone on sodium reabsorption m cultured collecting lenal duct cell7 27 Recently, it was shown that infusion of aldosterone mto rats with a remnant kidney increased blood pressure, protemuna, and glomerulosclerosis and neutralized the beneficial effects of Ang II blockade 28 The mechanism of aldostetone'5 pathological effects 1s unknown but might be due to ytlmulation of TGF-/3 production m the kidney Angiotensin II and Renal Fibrosis: Insights From Angiotensin II Blockade
As scientific data supporting the central role of TGF-/3 m fibrotic &ease have increased m recent years, so has evidence supporting the role of Ang II m renal and cardiac fibrosis Much of the Ang II-fibrosis connection has come from animal and recently from human studies on the therapeutic effects of Ang II blockade As early as 1986, using the remnant kidney model of progressive renal disease, Anderson et a12" showed that ACE mhlbitors slowed progression of disease At present, more than 40 publications have shown the efficacy of angletemm blockade m essentially every animal model of renal disease ' In addition, data from human stuchey are now available that support the animal work A large number of studies of both normotensive and hypertensive diabetic patients have been pubhshed 3"-4(' Other reports, first m renal scleroderma crls1s4' and later m glomerulonephrms,"* hypertensive renal disease,43 sickle cell nephropathy,"'
IgA nephropathy,45 and very recently human lmmunodeficlency virus-associated nephropathy,'"-" all rndlcate that angiotensm blockade slows progrersion of renal fibrosis While Ang II-mediated hypertension has long been known to lead to glomerular injury and sclerosis,"" it has not been entirely clear whether anglotensm blockade reduces fibrosis solely through controlhng glomerular hypertension and thereby glomerular injury, or whether pressure-independent, as well as pressure-dependent, mechamsms are operating There were early suggestions that glomerular hypertension and qclerosls did not neceSSarlly coexist m the same glomerulus and that ACE mhlbltlon can reduce sclerosis without altering glomeruldr pre55ure 5" 5' The efficacy of angiotensm blockade m nomiotenslve dlabetlc subjects also cuggested that pressuremdependent effects were operating, but did not prove this because systemic blood preccure does not necessarily reflect glomerular capillary pressures 5"5' Recent data, however, obtamed from m vitro stucheq m which pressure 1s not a factor, have plovlded strong support fol pressure-independent actlonc of Ang II How Much Reduction of TGF-P Can Be Achieved With Angiotensin II Blockade?
If one accepts reduction of TGF-/3 OverexpresSion as a vahd and potentially useful therapeutic target, one might ask how much reduction can be achieved with conventional therapies Specifically, can Ang II blockade normahze TGF-/3 Although answering this question m humans has been dlfflcult to date, there 1s a preliminary report showing reductions m unnary TGF-P m patients treated with ACE mhibmon 45 We are aware of 11 publications m which TGF-/3 expression has been measured m animals treated with either ACE mhibition or AT, receptor antagoms(5 s*-'* By using numbers or by estimating from graphs presented m these pubhcatlons, the approximate reduction of TGF-/3 overexpression achieved by these treatments was determmed The results are shown m the Table  Interestingly , m most of these studies, TGF-P levels remained somewhat elevated and, while disease seventy was reduced m all cases, considerable disease remarried These findmgs are comlstent with human studies showing that ACE mhibltors slow, but do not halt, disease Although there are many possible explanations for these findings, an obvious one 1s that these therapies have been designed with blood pressure reduction as their target Based on new data presented above, one can ask whether greater chsedse reduction can be achieved if TGF-P rather than blood prersure 1s the therapeutic target
We have approached this quesuon by usmg a rat model m which a single inJection of ATS 1s used to induce glomerulonephritis The ATS recognizes an epitope on the surfice of rat mesangial cells and lmtlates a complement-dependent lysls of a portion of the mesangial cells This tissue inJury IS followed by a fibrotic repair process involving increases m TGF-P expresslon, increased fibronectm, collagen and PAI-synthesis, and marked deposmon of extracellular matnx within the mesanglum by 6 days after disease induction This model has been used by us to demonstrate the importance of TGF-P m tissue fibrosis Overexpresslon of TGF-P has been confirmed m essentially every model of renal fibrosis and m a large number of human fibrotic condition? ' We recently set out to ask the questlon of how much reduction of TGF-P 1s possible with ACEI indicates angiotensm-converting enzyme mhlbdor, AT,RA, anglotensm II type 1 receptor antagonist, DOCA, deoxycorticosterone acetate, SHR, spontaneously hypertensive rat, SP, stroke prone, Um-Nx, unilateral nephrectomized, and CsA, cyclosporm A Ang II blockade We treated animals with increasing doses of either the ACE mhlbltor enalapnl or the AT, receptor antagonist losartan beginning 24 hours after disease induction with ATS Interestingly, prehmmary data indicate that increasing the dose of either drug above those usually used m such experiments does further reduce TGF-/3 overexpresslon The idea that higher doses of these drugs than used to reduce blood pressure can more effectively reduce fibrosis was also found m several earlier stu&es However, the maximum TGF-/3 reduction possible m our study was only about 50% Cl These findings are quite consistent with those presented m the Table, although none of those studies specifically tried to maximize TGF-/3 reduction
We anticipate that these preliminary data will be confirmed and that similar data will appear using other animal models of renal fibrosis If this occurs, it will be quite clear that Ang II blockade alone 1s not sufficient to halt renal fibrosis
Molecular
Interactions Between IUS and TGF-j3 in the Kidney Why 1s it that Ang II blockade 1s only partially effective m reducing TGF-P and fibrosis? As discussed above, a rapidly mcreasmg body of recent work supports the notlon that RAS and TGF-P are far more mtlmately interconnected than had been previously imagined The m vitro components of this work have strongly supported earlier suggestions that glomerular pressure 1s only part of the picture Studies at the molecular level have already explained some RAS-TGF-/3 mteractlons, while new connections provide fascinating questions for future research The mteractlons and potential mteractlons are shown m Fig 2 
Angiotensin
II and TGF-P Early m vitro suggestions that Ang II 1s a fibrogemc molecule came from demonstrations that when added to cultured murme mesanglal cells, an increase m collagen synthesis 1s seen 64 That same year, as the studies hnkmg TGF-P overexpresslon and fibrosis were increasing, it was reported that Ang II upregulates TGF-/3 production and increases TGF-P actlvatlon when added to cultured vascular smooth muscle cells 65
We then postulated that Ang II upregulates TGF-/3, mdependently of pressure, and that this increase m TGF-P leads to extracellular matnx protein production and deposltlon Usmg cultured rat mesangal cells, we confirmed the work with vascular smooth muscle cells by showing that Ang II-induced tune-and dose-dependent increases m TGF-/3 mRNA and TGF-P activation ' In addition, lagging slightly behind the TGF-P increases were increases m mRNAs for matrix proteins biglycan, fibronectm, and collagen I, which were shown to result m increased protein production by lmmunopreclpltatlon and electrophoresls of newly synthesized, radlolabeled fibronectm and collagen When neutralizing antibody to TGF-P was added to the cultures, the matnx protein increases were completely blocked m the case of fibronectm and about 77"/0 blocked m the case of collagen I ' Thus, the Ang II-medlated increases m matrix protein production are almost certainly medlated by TGF-P These data provided an Important mlssmg link between Ang II and fibrosts Ang II may also interact with other cytokmes that might be involved m pathologcal processes A number of m vlvo expenments have confirmed this m vitro work Using the tive sixths nephrectomy, or remnant kidney, model m the rat, m situ hybrtdlzatlon and Immunohlstochemlstry studies were done over time In early disease when sclerosis 1s not present, marked elevations m glomerular endothehal cell anglotensmogen mRNA were seen to be co-localized with increases m TGF-P mRNA Later, TGF-/3
Figure 2. Molecular interactions between the RAS and TGF-P mRNA was more widely mcreased and colocahzed with stammg for fibrotic matrix components lammm and fibronectm.16 These data suggested a pathological cascade m which reduced renal mass results m hyperperfuslon
The hyperperfuslon causes glomerular endothehal cell inJury, perhaps through shear stress on cell walls This mJury results m mductlon of Ang II, then TGF-/3 and increased matnx protein synthesis and deposltlon This cascade 1s supported by the findmg that an Ang II receptor antagonist markedly reduces disease Although this study 1s particularly nice because it shows increases m anglotensmogen mRNA at the site of mJury, a large number of studies have now shown that Ang II blockade decreases overexpresslon of TGF-P These studies, shown m the Table, used ammal models with a wide range of etlologles In all cases, Ang II blockade reduced TGF-P, making it likely that Ang II blockade will reduce TGF-P overproduction at least to some extent m all fibrotic renal diseases While this does not prove that Ang II causes fibrosis m all of these diseases, it does suggest a strong blologcal linkage between Ang II and TGF-P, which 1s very relevant to renal fibrotic diseases Angiotensin
II and the Plasmin Protease System
Plasmm has long been investigated as a fibnnolytlc enzyme important m dlssolutlon of clots after wounding Plasmm 1s generated from plasmmogen by the enzymatic action of plasmmogen activators, which are Inhibited by PAIs The generation of plasmm, and thus its action as a protease, are determined by the balance of plasmmogen activators and PAIs 66 Interestingly, the mhlbltor of plasmm generatlon, PAI-I, hke Ang II and TGF-P, can be considered a "911" molecule, m that it 1s rapidly increased at the site of wounding where it acts to stabilize the fibrin clot, which helps to stop hemorrhage, provides a temporary seal against bacterial mvaslon, and serves as a scaffoldmg for platelet aggregation and as a temporary matrix Again, as with Ang II and TGF-/3, a relatively new role for this system has been elaborated that 1s highly relevant to fibrotic diseases In addition to degrading fibrin, plasmm acts on a wide range of extracellular matrix proteins It also cleaves some procollagenases to produce active molecules that degrade collagens The importance of plasmm m turnover of the mesanglal matrix was recently shown by studies m which mesanglal cells were plated onto radioactive matrices The turnover of matnx was measured by the appearance of radlolabeled degradation products mto the culture supernatant These studies showed that mesangal matnx turnover 1s related to plasmm generation and that PAI-I levels are a maJor determinant of the plasmm generated 67
Earlier work from our laboratory had indicated that m response to added TGF-/3, isolated, cultured glomeruh show a rapid and marked increase m PAI-I mRNA and protem 68 In addition, using the ATS model of glomerulonephntls m the rat, we showed that by day 3 of disease, glomerular PAImRNA and protein were greatly elevated compared with levels m normal control rats The ability of culture supernatant from isolated nephntlc glomeruh to degrade casem was also markedly reduced, suggesting that these PAI-I elevations &d m fact lead to decreased plasmm proteolytlc actlvlty 's Marked increases m PAI-I expression m renal fibrotic diseases have now been shown m a number of anlmal'7~'970 and human studies Increased lmmunohlstochemlcal stammg of PAI-I m human renal biopsy tissues has now been shown m crescentlc nephropathles, acute and chronic transplant rgectlon, diabetic nephropathy, IgA nephropathy, lupus nephropathy, focal sclerosis, and human lmmunodeficlency vuusassociated nephropathy, making PAI-I lmmunostammg a very useful marker of fibrosis 71-74 Also supportmg a role for decreased plasmm generation contrlbutmg to matrix accumulation m fibrotic diseases m other tissues 1s a recent report showing that PAI-I-overexpressmg mice had more, and PAI-I deficient mice less, severe fibrosis m response to bleomycminduced lung mJury " Begmmng m 1991, reports of a linkage between Ang II and PAI-have appeared It has now been shown that Ang II leads to rapid and marked elevations m PAIexpression when added to cultured bram astrocytes, vascular endothehal cells, vascular smooth muscle cells, and bovine aortlc endothehal cefls [76] [77] [78] [79] However, the mterconnectlons between Ang II, TGF-/3, PAI-I, and fibrosis m renal cells were made very recently m two pubhcatlons
In experiments similar to those discussed above showing that TGF-/!I mediates Ang II-induced increases m matrix protein expression by cultured mesanglal cells, we showed that addition of Ang II caused a very rapid increase m PAImRNA, which appeared to precede the increase m TGF-P s" When antibody to TGF-P was added, the early increase m PAI-I expression remained, mdlcatmg that it was not mediated by TGF-P However, m the presence of antl-TGF-/3, the early increase was not sustained over time It was concluded that Ang II induces both an early TGF-P-mdependent increase m PAI-I and a later TGF-P-mediated increase In the context of "emergency" molecules, it 1s Interesting to speculate that Ang II produced or delivered to the site of mJury early lmmedlately Induces PAI-1, which helps to stabilize the fibnn clot Later, after Ang II has upregulated TGF-fi, this TGF-/3 sustains PAI-increases, reducing matnx degradation and thereby enhancing wound closure The orchestration and tlmmg of PAI-I , PA, and plasmm activity, however, are likely to be complex, since there 1s ample evidence that plasmmogen and plasmm carry out important functions m response to '"Jury 8'*82 That this early increase m PAI-I does, m fact, occur m response to renal mJury 1s suggested by prehmmary data from our laboratory, which showed a lo-fold increase m PAI-production by glomeruh isolated 6 hours after mductlon ofATS-glomerulonephntls (W A B, and N A N , unpubhshed observation, 1997) It will be interesting to determme, by blocking Ang II before mJury, whether this increase 1s Ang II mediated and whether blockmg this early PAI-I increase reduces or worsens the fibrotic disease that follows
Finally, m a model of radiation-induced renal mJury and scarring, dramatic increases m PAI-I mRNA were seen, which were partially ameliorated by ACE mhlbltlon or AT, receptor antagonists 'I Whether the PAI-I overexpresslon 1s mediated through TGF-/3 or 1s caused directly by Ang II as the authors argue, or 1s a combmatlon of the two, remains unclear Whatever the case, this study does, once again, suggest a relationship between Ang II and PAIthat 1s relevant to human fibrotic renal diseases
Aldosterone and Renal Fibrosis
Fascinating new data mentioned briefly above have appeared m which aldosterone overproduction has been linked to hypertension and glomerulosclerosls
In the remnant kidney model, aldosterone levels more than lo-fold above normal were seen When the ACE mhlbltor enalapnl and the AT, receptor antagonist losartan were given m combmatlon, aldosterone levels and disease seventy as measured by protemuna, systemic blood pressure, and glomerulosclerosls were decreased compared with those m untreated remnant kidney animals " However, when aldosterone infusion was added to enalapnl and losartan, disease seventy increased to the level of untreated rats These data suggest that aldosterone may have fibrogemc effects Independent of Ang II and clearly raise the question of whether aldosterone upregulates TGF-P expression Because admmlstratlon of the aldosterone receptor antagonist splronolactone did not block glomerulosclerosls but did transiently reduce protemuna, arterial pressure, and cardiac hypertrophy, the fibrotic actions of aldosterone and the possible mductlon of TGF-P must occur through channels other than the classic aldosterone receptor m the distal tubule
Renin and Prorenin as Fibrogenic Molecules
As with aldosterone, recent studies suggest that proremn or remn may have Ang II-independent actions to increase fibrosis First, transgemc, proremn-overexpressmg rats were found to be normotenslve but to develop severe glomerulosclerosls 23 Second, human recombmant remn, added to human mesangal cells, induces marked upregulatlon of PAIproduction, which 1s not only independent of Ang II but acts through a remn receptor on mesanglal cells, independent of the enzymatic site used by remn to convert angotensmogen to angotensmogen I 83 It 1s tempting to speculate that remn also upregulates TGF-/3 expresslon That this may, m fact, be the case 1s also suggested by findings that TGF-P and remn stammg m the JGA are both increased, independent of Ang II, m response to water depnvatlon" and potassmm depletion l9
TGF-P as a Renin Secretagogue
Finally, several article have been published suggesting that TGF-/3 enhances remn release In an early article using renal cortical slices, TGF-/3 was shown to cause remn release " More recently, addition of TGF-P to short-term culture of Juxtaglomerular cells was shown to increase remn release from these cells " These studies suggest that TGF-j3 may be an important factor m remn release, however, the relevance of this mteractlon to fibrotic disease 1s unknown In summary, new data suggest that Ang II exerts pressureindependent effects on renal fibrosis through upregulation of TGF-/3 which, m turn, leads to tissue fibrosis In addition, Ang II has direct effects on PAI-production, which may also play a role m accumulation of pathologcal extracellular matnx through decreasing the actions of plasmm to degrade matrix and to activate collagenases Although far from conclusive, new data suggest that the RAS components aldosterone, proremn, and remn may be intimately connected with TGF-/3 production and fibrotic matnx accumuiatlon It 1s interesting to speculate that these remarkable mterconnectlons between the RAS and TGF-j3 anse evolutlonarlly from the importance of restonng homeostasls and effecting rapid wound closure to avoid sepsis m response to injury In that preventing blood loss and sepsis was hkely to have been a maJor evolutionary advance, it 1s not surprising that there may be redundancy m these systems, such that If one arm 1s blocked, others can adequately take over the mlssmg function Such redundancy appears quite commonly m nature as shown by studies using a great number of mouse lines, where genes thought to have been crltlcal to survival are knocked out, and the animals are born and develop with mmlmal abnormalmes Therefore, when this "911" system wrth all its mterconnectlons remains activated, as it may well do m renal fibrotic diseases, therapies aimed at more than one arm will be necessary to effectively halt, rather than merely slow, disease 
